Payment overview · 2025
General Payments
$29.85
1 reported records · 1 companies
Healthcare provider profile · identity verified
Pedro C Falla, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · NEW BEDFORD, MA · NPI 1811096977
Verified facts
What the public records show
CMS Open Payments records show Pedro C Falla, M.D. received $29.85 in general payments during 2025 across 1 reported records.
ABBVIE INC. accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Linzess by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $29.85 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $29.85 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $29.85 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $29.85 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 951 | 315 |
| Amlodipine Besylate | Amlodipine Besylate | 666 | 224 |
| Losartan Potassium | Losartan Potassium | 604 | 189 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 598 | 194 |
| Omeprazole | Omeprazole | 527 | 181 |
| Lisinopril | Lisinopril | 453 | 151 |
| Pantoprazole Sodium | Pantoprazole Sodium | 407 | 124 |
| Metoprolol Succinate | Metoprolol Succinate | 366 | 109 |
| Metformin Hcl | Metformin Hcl | 352 | 118 |
| Levothyroxine Sodium | Levothyroxine Sodium | 318 | 102 |
| Furosemide | Furosemide | 306 | 97 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 239 | 88 |
| Gabapentin | Gabapentin | 235 | 64 |
| Hydrochlorothiazide | Hydrochlorothiazide | 229 | 74 |
| Trazodone Hcl | Trazodone Hcl | 225 | 67 |
| Glimepiride | Glimepiride | 188 | 60 |
| Trulicity | Dulaglutide | 177 | 42 |
| Ezetimibe | Ezetimibe | 175 | 65 |
| Metoprolol Tartrate | Metoprolol Tartrate | 175 | 54 |
| Fluticasone Propionate | Fluticasone Propionate | 170 | 66 |
| Baclofen | Baclofen | 161 | 59 |
| Alendronate Sodium | Alendronate Sodium | 158 | 49 |
| Sertraline Hcl | Sertraline Hcl | 154 | 59 |
| Ibuprofen | Ibuprofen | 147 | 60 |
| Tramadol Hcl | Tramadol Hcl | 146 | 35 |
| Famotidine | Famotidine | 135 | 49 |
| Eliquis | Apixaban | 131 | 33 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 129 | 31 |
| Simvastatin | Simvastatin | 123 | 43 |
| Ondansetron Hcl | Ondansetron Hcl | 120 | 40 |
| Ventolin Hfa | Albuterol Sulfate | 117 | 39 |
| Tamsulosin Hcl | Tamsulosin Hcl | 114 | 37 |
| Mirtazapine | Mirtazapine | 113 | 33 |
| Citalopram Hbr | Citalopram Hydrobromide | 109 | 34 |
| Methylprednisolone | Methylprednisolone | 109 | 89 |
| Lorazepam | Lorazepam | 102 | 33 |
| Montelukast Sodium | Montelukast Sodium | 102 | 33 |
| Pravastatin Sodium | Pravastatin Sodium | 100 | 33 |
| Clonidine Hcl | Clonidine Hcl | 97 | 29 |
| Doxazosin Mesylate | Doxazosin Mesylate | 97 | 38 |
| Meloxicam | Meloxicam | 97 | 35 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 89 | 43 |
| Jardiance | Empagliflozin | 88 | 24 |
| Meclizine Hcl | Meclizine Hcl | 85 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 84 | 25 |
| Alprazolam | Alprazolam | 83 | 16 |
| Metformin Hcl Er | Metformin Hcl | 82 | 29 |
| Ozempic | Semaglutide | 80 | 22 |
| Diclofenac Sodium | Diclofenac Sodium | 79 | 32 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 78 | 30 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 75 | 23 |
| Allopurinol | Allopurinol | 74 | 18 |
| Januvia | Sitagliptin Phosphate | 71 | 24 |
| Sucralfate | Sucralfate | 65 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 65 | 13 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 64 | 27 |
| Quetiapine Fumarate | Quetiapine Fumarate | 63 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 63 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 62 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 61 | 17 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 56 | 18 |
| Valsartan | Valsartan | 55 | 18 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 54 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 54 | 28 |
| Buspirone Hcl | Buspirone Hcl | 51 | 12 |
| Carvedilol | Carvedilol | 51 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 51 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 51 | 19 |
| Glipizide | Glipizide | 50 | 18 |
| Potassium Chloride | Potassium Chloride | 49 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 49 | 16 |
| Breo Ellipta | Fluticasone/Vilanterol | 46 | 11 |
| Bumetanide | Bumetanide | 46 | 15 |
| Symbicort | Budesonide/Formoterol Fumarate | 46 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 45 | suppressed |
| Azithromycin | Azithromycin | 43 | 39 |
| Bupropion Hcl Sr | Bupropion Hcl | 42 | 13 |
| Oxycodone Hcl | Oxycodone Hcl | 42 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 42 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 41 | 11 |
| Nystatin | Nystatin | 41 | 21 |
| Finasteride | Finasteride | 40 | suppressed |
| Glipizide Er | Glipizide | 39 | 15 |
| Valacyclovir | Valacyclovir Hcl | 39 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 38 | 34 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 37 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 36 | 12 |
| Clonazepam | Clonazepam | 36 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 35 | suppressed |
| Hydrocortisone | Hydrocortisone | 35 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 35 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 34 | 29 |
| Farxiga | Dapagliflozin Propanediol | 34 | 14 |
| Bupropion Xl | Bupropion Hcl | 33 | suppressed |
| Naproxen | Naproxen | 33 | suppressed |
| Prednisone | Prednisone | 33 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 32 | suppressed |
| Atenolol | Atenolol | 31 | 12 |
| Azelastine Hcl | Azelastine Hcl | 31 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 31 | suppressed |
| Fenofibrate | Fenofibrate | 31 | suppressed |
| Pregabalin | Pregabalin | 31 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 29 | suppressed |
| Vascepa | Icosapent Ethyl | 29 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 29 | 13 |
| Aripiprazole | Aripiprazole | 28 | suppressed |
| Diazepam | Diazepam | 28 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 28 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 28 | suppressed |
| Nifedipine Er | Nifedipine | 27 | suppressed |
| Xarelto | Rivaroxaban | 27 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 26 | 22 |
| Clobetasol Propionate | Clobetasol Propionate | 26 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 26 | suppressed |
| Linzess | Linaclotide | 26 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 26 | suppressed |
| Celecoxib | Celecoxib | 25 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 24 | suppressed |
| Lidocaine | Lidocaine | 24 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 23 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 22 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 21 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 21 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 20 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Eszopiclone | Eszopiclone | 19 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 19 | suppressed |
| Levemir Flexpen | Insulin Detemir | 19 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 19 | suppressed |
| Ketoconazole | Ketoconazole | 18 | suppressed |
| Lactulose | Lactulose | 18 | suppressed |
| Lamotrigine | Lamotrigine | 18 | suppressed |
| Risperidone | Risperidone | 18 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 17 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Verapamil Er | Verapamil Hcl | 17 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 16 | suppressed |
| Pulmicort Flexhaler | Budesonide | 16 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Nystop | Nystatin | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | suppressed |
| Nabumetone | Nabumetone | 14 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Folic Acid | Folic Acid | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Cephalexin | Cephalexin | 12 | 11 |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 12 | 11 |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Carbamazepine Er | Carbamazepine | 11 | suppressed |
| Loperamide | Loperamide Hcl | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Spironolactone | Spironolactone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $29.85 · 1 records | ABBVIE INC. | QULIPTA, UBRELVY | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error